The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

Description

The objective of this study is to test the effects of caffeine on neurocognitive and clinical recovery after major surgery. Specifically, this trial tests the primary hypothesis that caffeine will reduce the incidence of postoperative delirium.

Conditions

Postoperative Delirium, Postoperative Cognitive Dysfunction, Mild Cognitive Impairment

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of this study is to test the effects of caffeine on neurocognitive and clinical recovery after major surgery. Specifically, this trial tests the primary hypothesis that caffeine will reduce the incidence of postoperative delirium.

The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

Condition
Postoperative Delirium
Intervention / Treatment

-

Contacts and Locations

Ann Arbor

Michigan Medicine, Ann Arbor, Michigan, United States, 48109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult (\>/= 70 years old) undergoing non-cardiac, non-intracranial neurologic, non-major vascular surgery requiring general anesthesia with a planned admission for at least 48 hours.
  • 2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  • 3. Provision of signed and dated informed consent form.
  • 1. Emergency surgery
  • 2. Outpatient surgery
  • 3. Severe cognitive impairment precluding the capacity for informed consent
  • 4. Seizure disorder history
  • 5. Intolerance or allergy to caffeine (based on subjective reporting or objective documentation)
  • 6. Weight \>130 kg (as a 3 mg/kg dose would approach the upper limit of daily intake recommended by the FDA)
  • 7. Enrollment in conflicting research study
  • 8. Patients in acute liver failure
  • 9. Acute kidney injury preoperatively
  • 10. Diagnosis of pheochromocytoma
  • 11. Severe audiovisual impairment
  • 12. Non-English speaking

Ages Eligible for Study

70 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Michigan,

Phillip Vlisides, MD, PRINCIPAL_INVESTIGATOR, Assistant Professor of Anesthesiology

Study Record Dates

2026-05-31